AMGEN INC. $1,250,000,000 2.125% SENIOR NOTES DUE 2017 $750,000,000 3.625% SENIOR NOTES DUE 2022 $1,000,000,000 5.375% SENIOR NOTES DUE 2043 Underwriting AgreementUnderwriting Agreement • May 15th, 2012 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,250,000,000 principal amount of the 2.125% Senior Notes due 2017 of the Company (the “2017 Notes”), an aggregate of $750,000,000 principal amount of the 3.625% Senior Notes due 2022 of the Company (the “2022 Notes”) and an aggregate of $1,000,000,000 principal amount of the 5.375% Senior Notes due 2043 of the Company (the “2043 Notes”, and together with the 2017 Notes and the 2022 Notes, collectively,
